Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
McKinsey
Mallinckrodt
Express Scripts
Boehringer Ingelheim

Last Updated: December 11, 2019

DrugPatentWatch Database Preview

Patent: 7,790,675

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 7,790,675
Title:Method for increasing frataxin expression
Abstract: Use of human erythropoietin or a derivative of erythropoietin having the biological activity of human erythropoietin of increasing the expression of frataxin for the production of a pharmaceutical preparation for the treatment of Friedreich\'s ataxia or for the treatment or prevention of a disease associated with Friedreich\'s ataxia.
Inventor(s): Scheiber-Mojdehkar; Barbara (Vienna, AT), Sturm; Brigitte Nina (Vienna, AT)
Assignee: Medizinische Universitaet Wien (Vienna, AT)
Application Number:11/718,870
Patent Claims:see list of patent claims

Details for Patent 7,790,675

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen ARANESP darbepoetin alfa VIAL; SUBCUTANEOUS 103951 010 2001-09-17   Start Trial Medizinische Universitaet Wien (Vienna, AT) 2024-11-09 RX search
Amgen ARANESP darbepoetin alfa VIAL; SUBCUTANEOUS 103951 009 2001-09-17   Start Trial Medizinische Universitaet Wien (Vienna, AT) 2024-11-09 RX search
Amgen ARANESP darbepoetin alfa VIAL; SUBCUTANEOUS 103951 008 2001-09-17   Start Trial Medizinische Universitaet Wien (Vienna, AT) 2024-11-09 RX search
Amgen ARANESP darbepoetin alfa VIAL; SUBCUTANEOUS 103951 007 2001-09-17   Start Trial Medizinische Universitaet Wien (Vienna, AT) 2024-11-09 RX search
Amgen ARANESP darbepoetin alfa VIAL; SUBCUTANEOUS 103951 006 2001-09-17   Start Trial Medizinische Universitaet Wien (Vienna, AT) 2024-11-09 RX search
Amgen ARANESP darbepoetin alfa VIAL; INTRAVENOUS 103951 005 2001-09-17   Start Trial Medizinische Universitaet Wien (Vienna, AT) 2024-11-09 RX search
Amgen ARANESP darbepoetin alfa VIAL; INTRAVENOUS 103951 004 2001-09-17   Start Trial Medizinische Universitaet Wien (Vienna, AT) 2024-11-09 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Harvard Business School
Baxter
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.